Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that its management will participate in a virtual fireside chat at the B. Riley Securities’ Neuro & Ophthalmology Conference on April 27-28, 2022. The discussion will focus on advancements in their clinical programs targeting age-related diseases affecting the central nervous system and retina, particularly their lead candidate, CT1812. A webcast will be available for viewers, outlining the company's ongoing research and development efforts in Alzheimer’s disease and other conditions.
- Management participation in a major conference may enhance visibility and investor interest.
- Focus on clinical advancements for CT1812, targeting critical neurodegenerative diseases.
- Dependence on ongoing clinical trials introduces uncertainty regarding future product efficacy and market approval.
PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that members of its management team will participate in a virtual fireside chat at the B. Riley Securities’ Neuro & Ophthalmology Conference taking place from April 27-28, 2022.
Management’s conversation during the event will cover the progress on clinical programs within Cognition’s neurodegenerative and ophthalmological drug pipeline. A webcasts of this fireside chat will be available at https://www.webcaster4.com/Webcast/Page/2875/45362 and archived on the “Events and Presentations” section of the Cognition Therapeutics website. Details of the event are as follows:
Presentation date: Wednesday, April 27, 2022
Time: 3:00 PM ET
About Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and are available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact Information:
Cognition Therapeutics, Inc.
info@cogrx.com
Aline Sherwood (media)
Scienta Communications
asherwood@scientapr.com
Lisa Sher / Daniel Kontoh-Boateng (investors)
Tiberend Strategic Advisors, Inc.
lsher@tiberend.com / dboateng@tiberend.com
FAQ
What is Cognition Therapeutics discussing at the B. Riley Conference?
When is Cognition Therapeutics' virtual fireside chat?
Where can I watch the Cognition Therapeutics fireside chat?
What is the focus of Cognition Therapeutics' drug pipeline?
What therapeutic area is CT1812 targeting?
